These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34246076)

  • 1. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
    Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
    Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
    Fu H; Cheng L; Sa R; Jin Y; Chen L
    J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
    Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
    Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
    Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
    Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.